Background: Alzheimer's disease (AD) and related dementias can have long preclinical phases; thus, midlife intervention and prevention methods could prove efficacious. Multiple health-related lifestyle factors have been associated with risk for AD. However, research on lifestyle factors has focused on clinical outcomes such as cognitive decline, mild cognitive impairment and/or AD dementia; their associations with potential early changes in cerebrospinal fluid (CSF) biomarkers are less understood. Our aim was to determine whether key lifestyle factors are associated with CSF biomarkers for neurodegeneration, glial activation, and neuroinflammation.
Method: Participants were N=653 adults (aged 43-93 years) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center, two on-going, longitudinal studies of preclinical AD. We assessed CSF biomarkers using the NeuroToolKit (NTK), a panel of robust prototype biomarker assays (Roche Diagnostics International, Switzerland). Participants completed demographic and health questionnaires and a physical assessment (Table 1). Linear regression models assessed standardized effects of associations between lifestyle factors (education, smoking, obesity, and physical activity) and CSF biomarkers, adjusting for age and sex.
Result: After correcting for false discovery rate, preliminary results (Table 2) showed that participants with more years of education had higher CSF Aβ42/40 and lower pTau181 concentrations (Est. = 0.006, or 1 unit increase in Aβ42/40 per year increase in education, 95% confidence interval: 0.001-0.011; p =.008, adjusted p = .061; Est.= -0.007, or 1 unit decrease in pTau181 per year increase in education, 95% confidence interval: -0.013--0.002; p=.026, adjusted p=.061). No other biomarker associations withstood correction for multiple comparisons.
Conclusion: Education has been discussed as an early modifiable risk factor for AD, likely through a mechanism of cognitive resilience. We found that higher education was associated with less AD proteinopathy (e.g. better Ab42/40 and pTau181 profiles). Future studies should explore the potential underlying mechanisms for this association. Longer follow-up will help to understand how these findings relate to biomarker levels and cognitive changes at a later stage of disease progression.
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.